This study explores the application of artificial intelligence technology for the quantitative analysis of immunohistochemical markers to differentiate between mantle cell lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma. Utilizing an AI-based platform, the research analysed the expression of CD3, CD5, CD10, CD20, CD23, Cyclin D1, BCL-2, BCL-6 and Ki-67 in 91 samples from 84 patients. The findings demonstrate that, compared to manual interpretation, the AI system provides more objective, reproducible and accurate measurement results. Additionally, this study introduces a virtual dual immunohistochemical labelling technique for simultaneous antigen visualization. Although limited by its single-centre retrospective design, the research establishes a promising AI-assisted framework that enhances the accuracy, standardization and diagnostic efficiency in distinguishing between these two clinically distinct lymphomas.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: